Apretude (Injectable PrEP) | OSRA Medical

OSRA Medical provides fast, easy, and confidential access to Apretude, the injectable PrEP, for everyone in the San Francisco area. Contact us today to secure your access to the PrEP injection in San Francisco.

Why Choose Injectable PrEP Over Existing Oral Regimens for PrEP?

Injectable PrEP is a form of PrEP (Pre-Exposure Prophylaxis) that is given every other month after initiation injections have been given 1 month apart, for 2 consecutive months. It’s important to attend all appointments.

It is the first and only long-acting, injectable PrEP for reducing the risk of HIV-1 acquisition.

It is designed to continuously help prevent HIV-1 acquisition when taken every other month.

No daily PrEP pills to remember or keep track of. Receive your Apretude injection every other month.

Studied in HIV-1 negative cisgender men, transgender women, and cisgender women at risk of getting HIV-1.

“Injectable PrEP was proven to be at least as effective as existing oral regimens of PrEP to reduce the risk of getting HIV.”

Injectable PrEP VS Oral PrEP

Injectable PrEP was compared to daily oral PrEP injection in one of the most diverse PrEP clinical studies ever observed. Find some quick statistics comparing Apretude VS PrEP injection below:

Study #1

In Study 1, 4,566 cisgender men and transgender women were on the product for an average of 1.3 years. During the time they were at risk of getting HIV, there was a:

  • 69% reduction in risk of getting HIV compared to a daily oral PrEP, meaning better protection.
  • HIV transmissions occurred 3X less often with Injectable PrEP compared to a daily oral PrEP.

Study #2

In Study 2, 3,224 cisgender women were on the product for an average of 1.2 years. During the time they were at risk of getting HIV there was a:

  • 90% reduction in risk of getting HIV compared to a daily oral PrEP, meaning better protection.
  • HIV transmission occurred 12X less often with Apretude injection compared to a daily oral PrEP.

Our Mission

Dr. Nas founded OSRA Medical in 2019 to regain his relationship with his patients and free his practice of back-end affiliations with payers and large corporations.ions.

His dream of being a doctor who represents the LGBTQ+ community and is truly available to meet his patients’ individual, complex needs, regardless of gender, was not possible in a traditional practice setting.

Schedule a free personalized appointment in San Francisco with OSRA Medical today and meet Dr. Nas.

Injectable PrEP FAQs

Do you have a question about injectable PrEP? Take a look at our frequently asked questions below, or schedule an appointment with OSRA Medical!

It is used to help prevent HIV-1 acquisition. To further reduce your risk of sexually getting HIV-1 infection, it’s important to know your status, get regularly tested for other sexually transmitted infections (STIs), and practice safer sex by using condoms.

Get tested for HIV prior to starting Injectable PrEP because you must be HIV-1 negative to start. Your healthcare provider will test you for HIV before each injection, as well as if you are diagnosed with an STI while taking it.

It is given every other month by a healthcare provider after initiation injections have been given 1 month apart for 2 consecutive months.

It’s important to attend all appointments.

Across both studies, the most common side effect was injection-site reactions.

Injection-site reactions were reported by 82% of participants who received Injectable PrEP in Study 1 and 38% of participants who received Apretude in Study 2.

Injection-site reactions included pain, tenderness, hardened mass or lump, swelling, bruising, redness, itching, warmth at the injection site, induration, loss of sensation at the injection site, abscess, and discoloration. Results may vary.

In Study 1, 41% of participants reported a mild injection-site reaction, 56% of participants reported a moderate injection-site reaction, and 3% of participants reported severe injection-site reactions.

In Study 2, 66% of participants reported a mild injection-site reaction, 34% of participants reported a moderate injection-site reaction, and <1% of participants reported severe injection-site reactions.

3% of participants in Study 1 and no participants in Study 2 discontinued taking Injectable PrEP due to injection-site reactions being one of the Injectable PrEP side effects.

To learn more about the potential Apretude side effects, please visit https://apretude.com/.

Have additional questions? Please call us by clicking the link below!